Spyre Therapeutics (SYRE) EBIT (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of EBIT data on file, last reported at -$45.6 million in Q1 2026.

• Quarterly EBIT rose 14.8% year-over-year to -$45.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201.6 million (up 5.94% YoY) and the FY2025 annual result came in at -$209.6 million, changed 0.48% from the prior year.
• EBIT advanced to -$45.6 million in Q1 2026, from -$57.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$18.3 million in Q3 2023 to a low of -$159.2 million in Q2 2023.
• A 5-year average of -$46.5 million and a median of -$45.6 million in 2026 frame the typical range for EBIT.
• Annual changes were most pronounced in 2023 — EBIT plunged 610.19% — and 2024, when it surged 72.28%.
• Tracing SYRE's EBIT over 5 years: stood at -$19.2 million in 2022, then plunged by 139.61% to -$45.9 million in 2023, then slumped by 33.41% to -$61.3 million in 2024, then rose by 6.66% to -$57.2 million in 2025, then gained by 20.17% to -$45.6 million in 2026.
• The last three EBIT figures came in at -$45.6 million (Q1 2026), -$57.2 million (Q4 2025), and -$56.9 million (Q3 2025), per Business Quant data.